| Document |
Document Title |
|
WO/2016/033100A1 |
In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting ...
|
|
WO/2016/012362A1 |
The invention relates to cyano cycloalkyl penta-2,4-dienes, cyano cycloalkyl pent-2-en-4-ynes, cyano heterocyclyl penta-2,4-dienes and cyano heterocyclyl pent-2-en-4-ynes of general formula (I), or the salts thereof, where [X-Y], Q, R1, ...
|
|
WO/2016/008862A1 |
The invention relates to substituted vinyl and alkynyl cyanocycloalkanols and vinyl and alkynyl cyanoheterocyclylalkanols of general formula (I) or the salts thereof, wherein [X-Y], Q, R1, R2, A1, A2, V, W, m and n have the definitions s...
|
|
WO/2016/007534A1 |
The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the...
|
|
WO/2015/181186A1 |
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions con...
|
|
WO/2015/173392A1 |
The present invention relates to novel substituted oxindole derivativesof formula I, wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compound...
|
|
WO/2015/173393A1 |
The present invention relates to novel substituted oxindole derivatives of the formula I wherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substitue...
|
|
WO/2015/171372A1 |
The present invention provides novel solutions to the problem of recycling carbonylation catalysts in epoxide carbonylation processes. The inventive methods are characterized in that the catalyst is recovered in a form other than as acti...
|
|
WO/2015/159233A1 |
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R2, R3, n, and p are as defined herein, which are active as modulators of retinoid-related orphan re...
|
|
WO2015120822A1 |
Disclosed are water-soluble taxane derivatives, a method for treating tumor using same, use thereof as anti-tumor drugs and use thereof for preparing anti-tumor drugs. The water-soluble taxane derivatives have general formula(I-1), (I-2)...
|
|
WO/2015/120820A1 |
The present invention discloses a class of carboxylic acid derivatives and use thereof in preparation of prodrugs. The carboxylic acid derivatives have the general formula (I): R1 being H or an alkyl; X being H or F; Y being F or a fluor...
|
|
WO/2015/110446A1 |
The present invention relates to a novel process for the preparation of a compound of the formula (I) and pharmaceutically acceptable acid addition salts thereof, which is useful for prophylaxis and treatment of respiratory syncytial vir...
|
|
WO/2015/096553A1 |
The present invention belongs to the pharmaceutical field, and relates to an anti-multidrug resistance taxane anti-tumour compound and a preparation method thereof, in particular relates to a taxane compound having a structure as shown b...
|
|
WO/2015/087228A1 |
The present disclosure provides anisole and benzyl alcohol solvates of cabazitaxel and methods of their production. The solvates may be characterized by powder x-ray diffraction patterns. The present disclosure also provides methods for ...
|
|
WO/2015/078374A1 |
The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as desc...
|
|
WO/2015/074605A1 |
The present invention provides taxanes compounds with a formula (I) or formula (II) structure, a method for preparing the compounds, and the compound, and uses of medicinal salts thereof and solvates used as compositions of active ingred...
|
|
WO/2015/058960A1 |
The present invention relates to new crystalline forms of Cabazitaxel of formula (I). Specifically, the present invention provides four new crystalline solvate forms of Cabazitaxel, designated as form S2 (solvate with 2-methyltetrahydrof...
|
|
WO/2015/058961A1 |
The present invention relates to a new anhydrous crystalline form of Cabazitaxel of formula (I), designated as form H. A further object of the present invention is a processes for the preparation of the above mentioned form H by recrysta...
|
|
WO/2015/038493A1 |
The present disclosure relates to a dendrimer-based conjugate of the formula Vm-D-C-D'-(T-F)n, which is useful for tumor targeting drug delivery. The use of asymmetric dendrimers allow for specific targeting as well as synthetic reproduc...
|
|
WO/2015/031300A1 |
The invention encompasses antibacterial beta-lactones, methods of making, pharmaceutical preparations thereof, and methods of utilization of such compounds for the treatment of bacterial infections.
|
|
WO/2015/028960A1 |
The present invention generally relates to substituted heterocyclic derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as G-protein coupled recept...
|
|
WO/2015/020013A1 |
The present invention relates to a negative electrode for a lithium ion secondary cell, as well as a lithium ion secondary cell using the same. The negative electrode contains an oxetane compound represented by a prescribed formula, with...
|
|
WO/2015/000165A1 |
Provided are a stable transformation product of dimethoxy docetaxel mono-acetonate, crystalline forms thereof, and methods for the preparation of same. The stable transformation product and the crystalline forms thereof are higher in sta...
|
|
WO/2014/199401A2 |
The present invention provides an improved process for the preparation of 4α-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,13α-dihydroxy-7
β,10β-dimethoxy-9-oxo-11-taxene (7β,10β-dimethoxy-10-deacetoxybaccatin III). The present invention...
|
|
WO/2014/191989A1 |
A conjugate comprising docetaxel and biotin covalently linked to one another is disclosed, as well as uses thereof in the treatment of proliferative diseases and disorders such as cancer.
|
|
WO/2014/160649A1 |
This invention pertains generally to antibacterial organic compounds of Formula I as described herein, and pharmaceutical compositions containing such compounds. In certain aspects, the invention pertains to treating infections caused by...
|
|
WO/2014/150646A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2014/121884A1 |
The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states...
|
|
WO/2014/086122A1 |
Disclosed are a device and a method for continuously preparing a high-purity AKD without solvent. The device comprises a reactor for mixing and reacting raw materials continuously. The method comprises the following process steps: firstl...
|
|
WO/2014/088281A1 |
The present invention relates to a novel method for preparing cabazitaxel from 10-deacetylbaccatin III, and a novel intermediate therefor, and more specifically, to: a method which allows cabazitaxel to be more easily prepared in a high ...
|
|
WO/2014/074309A1 |
Latent dispersants were made by the hydrogenation of an alkyl ketene dimer, alkenyl ketene dimer, or ketene multimer. Adding the latent dispersant to paper or paperboard increased its resistance to water and water vapor while maintaining...
|
|
WO/2014/072996A2 |
The present invention relates to a novel process for preparation of cabazitaxel (I) starting from 10-Deacetyl baccatin or derivative that involves methylation of 7, 10 -OH groups. Also provided is a novel process using chiral bis-lactam ...
|
|
WO/2014/067207A1 |
Disclosed is a cabazitaxel crystalline, 7,10-dimethoxy docetaxel or (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropion
ic acid 4-acetoxy-2α-benzoxy-5β,20-epoxy-1-hydroxy-7β,10β-dimeth
oxy-9-oxo-11-taxene-13α-yl ester in th...
|
|
WO/2014/060445A1 |
The present invention relates to a method of purifying Orlistat comprising the steps of: a) providing an injection solution comprising crude Orlistat; b) injecting said injection solution into a reverse phase high performance liquid chro...
|
|
WO/2014/022237A1 |
The present invention is directed to an amorphous form of cabazitaxel, which can be prepared by dissolving a solid form of cabazitaxel in an organic solvent, and removing the organic solvent to dryness. The amorphous form of cabazitaxel ...
|
|
WO/2014/015760A1 |
The present invention relates to the field of medical chemistry, and discloses a preparation method for three crystal forms of cabazitaxel, that is, ester compound crystalline form J of cabazitaxel, hydrate crystalline form G of cabazita...
|
|
WO/2013/185202A1 |
This invention comprises novel compounds which inhibit the activity of anti-apoptotic Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases involving a defect in apoptosis, such as, for exam...
|
|
WO/2013/179819A1 |
Provided are a polymerizable monomer that can used for optical materials, resist materials, coating materials, laminate materials, and various other such purposes; and a method for producing the same. A (meth)acrylic acid ester compound ...
|
|
WO/2013/169531A1 |
This invention relates to methods for making oxetan-3-ylmethanamines having the formula (I) wherein R1? and R2? are as defined herein. The methods of the invention provide the compounds of formula (I) in high yields and under conditions ...
|
|
WO/2013/164172A1 |
Process for the production of a chemical compound from a carbon dioxide starting material, comprising the steps of a) providing a feed stream consisting mainly of carbon dioxide; b) electrolysing in an electrolysis stage the carbon dioxi...
|
|
WO/2013/162922A1 |
The present invention provides a method for the preparation of orally available pentacyclic taxane compounds, as well as intermediates useful in their preparation.
|
|
WO/2013/069027A9 |
Disclosed are processes towards Cabazitaxel (I) starting from 10-Deacetylbaccatin (III) that involve steps of either 7-OH monosilylation (passing through formula V) or 7,13-disilylation (passing through formulae XI, XII). Isopropanol Sol...
|
|
WO/2013/146981A1 |
The present invention provides a method that is for producing a laminate film and that that includes forming a layer by curing a liquid crystalline composition containing a liquid crystalline compound having a polymerizable group and tha...
|
|
WO/2013/143811A1 |
Compounds of the formula (I), in which the substituents are as defined in claim 1,are suitable for use as nematicides.
|
|
WO/2013/146651A1 |
The purpose of the invention is to provide a method for industrially manufacturing with high yield a (meth)acrylate containing a cyclic ether group, and to provide an active energy beam curable resin composition obtained by adding said a...
|
|
WO/2013/138243A1 |
The present disclosure encompasses bifunctional compounds resulting from the ring-expanding mono- and bis-carbonylation of glycidyl acrylates to afford the corresponding beta lactones and succinic anhydrides. Uses of the materials and po...
|
|
WO/2013/134534A2 |
The invention relates to solid state forms of Cabazitaxel and processes for preparing the solid state forms. The invention further relates to pharmaceutical compositions and formulations comprising one or more of the solid state forms.
|
|
WO/2013/128378A1 |
The present invention relates to phenyl alkanoic acid derivatives (the compounds of Formula (I)); and their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, or pharmaceutically acceptable salts, pha...
|
|
WO/2013/111157A1 |
The present invention provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimet
hoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate...
|
|
WO/2013/092941A1 |
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds f...
|
